Navigation Links
LetsTalkIBS.com Helps Patients Start the Conversation about Irritable Bowel Syndrome
Date:3/29/2010

New tools are now available on www.letstalkibs.com – including a “Describe How You Feel” tool – to help patients put their symptoms into words for a more constructive conversation with healthcare providers.

Chicago, Ill. (PRWeb) March 29, 2010 -- New tools are now available on www.letstalkibs.com to help patients living with irritable bowel syndrome (IBS) describe their symptoms to a healthcare provider and establish an effective treatment plan. IBS is a disorder characterized by symptoms including abdominal pain and discomfort, bloating, and changes in bowel habits such as constipation and/or diarrhea. While this condition affects nearly 1 in 5 Americans, many patients are uncomfortable talking about their IBS symptoms, making it challenging for healthcare providers to properly diagnose and treat patients.

In an effort to bridge this communication gap, letstalkibs.com is offering tools to help patients put their symptoms into words for a more constructive conversation with their healthcare providers. One such tool – a “Describe How You Feel” tool – enables patients to better identify and describe the way they are feeling by using images to represent symptoms of IBS.

“It is important for patients to have an open and honest conversation with their healthcare provider about their IBS symptoms. Once healthcare providers understand a patient’s symptoms and how they may impact daily life, including work productivity, social and physical activities and travel plans, they can better diagnose and treat each individual,” said Dr. Lauren Gerson, M.D., associate professor of medicine & gastroenterology, Stanford University School of Medicine. “The tools available on letstalkibs.com can help patients communicate their IBS symptoms more effectively, and enable them to take control of their health and get the help and support they need.”

For more information and tips about IBS, visit www.letstalkibs.com.

Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc.
Based in Deerfield, Ill., Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc. are subsidiaries of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. The respective companies currently market oral diabetes, insomnia, rheumatology and gastroenterology treatments and seek to bring innovative products to patients through a pipeline that includes compounds in development for diabetes, cardiovascular disease, gastroenterology, neurology and other conditions. Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. To learn more about these Takeda companies, visit www.tpna.com.

Multimedia Release: Multimedia Content Attached

To view the full multimedia news release, please visit www.starttalkingibs.com.

###

Read the full story at http://www.prweb.com/releases/2010/03/prweb3795784.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. Book explains how focus on strengths, not failures, helps teens succeed in school
2. Weight Counseling Plus Drug Helps Women Quit Smoking
3. VoiceNation Helps Non-Profits Gather Funding for Those in Need
4. Disabling Skp2 gene helps shut down cancer growth
5. SavATree, Once Again, Helps Clients Recover from Storm Damage
6. Flexible Floor-Cleaning Routine Helps School Prevent Spread of Infection
7. Georgia Dentist Uncovers Obscure Law That Helps Dental Patients With Severe Anxiety
8. National Safe Place Week Helps Prevent Teen Homelessness
9. Metabolife's New Green Tea + Vitamin D3 Helps Promote Bone Health and Supports Weight Management
10. Heat Therapy Helps Treat U.S. Soldiers Infections
11. Healing Wounds and Hearts: Warrior Weekend Helps Soldiers and Marines Relax and Recover
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... CA (PRWEB) , ... January 19, 2017 , ... ... Health, is now offering treatments for patients with sleep apnea and TMJ disorders. ... for dental and physical health. Dr. Rassouli provides personalized care to reduce the ...
(Date:1/19/2017)... ... January 19, 2017 , ... Sam & Associates Insurance Agency, a full ... clients in the California Bay Area, is launching a charity drive to raise awareness ... Heart disease is the primary killer of adult men and women in America, and ...
(Date:1/19/2017)... ... January 19, 2017 , ... St. Catherine’s Village announced that a limited ... a skilled nursing facility on the grounds of the St. Catherine’s Village campus in ... voted the best nursing home in Mississippi for the second year in a row ...
(Date:1/19/2017)... ... , ... The CHP suggests that California drivers can avoid hydroplaning as well ... increasing the space between themselves and other vehicles, according to a January 3 ... Hassanlou notes that, rain or shine, drivers should always incorporate safe driving practices in ...
(Date:1/19/2017)... ... , ... Sales Focus Inc. (SFI), a Maryland-based sales outsourcing company, announced today ... past 20 years SFI has been recognized as the world’s leader in Intelligent Sales ... the US market. The new clients include: Panacea Pro, Campseekers, Contentmart, Stress Pal, ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... URBANDALE, Iowa , Jan. 18, 2017 /PRNewswire/ ... announced that subsidiary Caretta Therapeutics plans, in the ... product. Venodol, a topical roll-on intended to provide ... to opioid and steroidal analgesics. It was developed ... Reid to commercialize products derived from snake ...
(Date:1/18/2017)... , Jan. 18, 2017  Kratom leaves, from ... family, are often used to prepare tea-like beverages ... several million Americans annually to increase alertness, enhance ... remedy for minor aches and pains. PinneyAssociates, review ... intended to assist FDA and DEA in determining ...
(Date:1/18/2017)... 18, 2017  Dermata Therapeutics, LLC, a biotechnology ... a variety of dermatological diseases, announces dosing the ... a Phase 2 acne rosacea study. DMT210 is ... proinflammatory cytokines in the skin responsible for the ... This clinical trial, DMT210-003, is a ...
Breaking Medicine Technology: